Latest Content

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Check out our pipeline updates from August!

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Review news in psychiatry from the last week.

Livestreamed insanity trials reshape public opinion, exposing myths, bias, and psychiatry’s educator role, in cases like the M’Naghten trial to the curent Clancy trial.

Drs Clark and Walton discuss ADHD in underrecognized groups, along with treatment and lifestyle options.

Meta faces an $18B teen-safety settlement, adding time limits, night and school modes, parental controls, and tighter age checks across Instagram and Facebook.

New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.

Recap Alzheimer disease updates from August.

High-profile infanticide trial fuels debate over postpartum illness, malpractice claims, and whether psychiatrists should be judged for patients’ crimes rather than care quality.

Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.